J. Ferlay, H. Shin, and F. Bray, Estimates of worldwide burden of cancer in 2008: GLOBOCAN, Int J Cancer, vol.127, pp.2893-917, 2008.

P. Salaün, R. Abgral, and O. Malard, Good clinical practice recommendations for the use of PET/CT in oncology, Eur J Nucl Med Mol Imaging, vol.47, pp.28-50, 2020.

M. Gauthé, M. Richard-molard, and W. Cacheux, Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers, Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver, vol.47, pp.443-54, 2015.

C. Deleau, B. Buecher, and C. Rousseau, Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence, Eur J Gastroenterol Hepatol, vol.23, pp.275-81, 2011.

P. P. Mainenti, M. Mancini, and C. Mainolfi, Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 tesla MR with extracellular and reticulo-endothelial cell specific contrast agents, Abdom Imaging, vol.35, pp.511-532, 2010.

D. V. Sahani, S. P. Kalva, and A. J. Fischman, Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and wholebody FDG PET, AJR Am J Roentgenol, vol.185, pp.239-285, 2005.

I. Floriani, V. Torri, and E. Rulli, Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis, J Magn Reson Imaging, vol.31, pp.19-31, 2010.

C. Bailly, P. Cléry, and A. Faivre-chauvet, Immuno-PET for clinical theranostic approaches, Int J Mol Sci, vol.18, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01636873

F. Kraeber-bodéré, C. Rousseau, and C. Bodet-milin, Front Pharmacol, vol.6, p.54, 2015.

C. D. Vrabie, M. Ceau?u, and A. Petrescu, The usefulness of immunohistochemistry in sporadic colorectal cancer, Romanian J Morphol Embryol Rev Roum Morphol Embryol, vol.49, pp.525-560, 2008.

S. Benchimol, A. Fuks, and S. Jothy, Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule, Cell, vol.57, pp.90970-90977, 1989.

E. A. Rossi, D. M. Goldenberg, and T. M. Cardillo, Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc Natl Acad Sci, vol.103, pp.6841-6847, 2006.

C. Bodet-milin, A. Faivre-chauvet, and T. Carlier, Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the Pretargeting parameters in a first-in-human trial, J Nucl Med, vol.57, pp.1505-1516, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01415668

C. Rousseau, D. M. Goldenberg, and M. Colombie, Initial clinical results of a novel immuno-PET theranostic probe in HER2-negative breast cancer, J Nucl Med, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02512957

F. Foubert, S. Gouard, and C. Saï-maurel, Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: comparison with 18FDG PET-CT, Oncotarget, vol.9, pp.27502-27515, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01981491

H. Karacay, R. M. Sharkey, and W. J. Mcbride, Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga, J Nucl Med, vol.52, pp.555-564, 2011.

D. Laessig, D. Nagel, and V. Heinemann, Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients, Anticancer Res, vol.27, pp.1963-1971, 2007.

M. Andersson, L. Johansson, and D. Minarik, Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors, EJNMMI Phys, vol.1, issue.9, 2014.

C. Bodet-milin, L. Ferrer, and A. Rauscher, Pharmacokinetics and d o s i m e t r y s t u d i e s f o r, CEA-expressing advanced lung cancer patients, vol.2, p.84, 2015.

A. Bardia, I. A. Mayer, and L. T. Vahdat, Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer, N Engl J Med, vol.380, pp.741-51, 2019.

R. Schoffelen, O. C. Boerman, and D. M. Goldenberg, Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results, Br J Cancer, vol.109, pp.934-976, 2013.